Please assess the completion status of the following clinical trial:

Trial Title: Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants aged 6 weeks to 12 months admitted in paediatric emergency~* First episode of acute bronchiolitis defined as: expiratory dyspnea with breath slowing and/or sibilants and/or crackles preceded by (or associated with) a nasopharyngitis more or less febrile~* Respiratory distress assessment index score (RDAI) of 4 to 15 after a nasopharyngeal clearance~* Agreement of at least one of the parents for his child to participate in biomedical research~* Affiliation to social security (beneficiary or entitled), except beneficiary of State medical help~Exclusion Criteria:~* Prematurity (less than 37 weeks of gestation)~* Antecedent of invasive respiratory ventilation during neonatal period~* Antecedent of lung or chronic cardiac pathology of wich rhythm disorder, acute obstructive cardiomyopathy and coronary insufficiency~* Immune deficiency~* Active viral infection (hepatitis, zona, herpes, varicella, HIV)~* Proven or suspected tuberculosis~* Exposure to varicella during 15 days before inclusion~* Severe distress (defined as one of following signs: a pulse rate \>200/min, respiratory rate \>80/min, RDAI score \>15, neurological disorders)~* Nebulization (aerosol spray) of Salbutamol or other bronchodilator treatment during the 24 hours before the inclusion~* Inhalation (spray) of Salbutamol during the preceding 24 hours~* Oral or inhaled corticosteroids during the preceding 2 weeks~* Previous episode of wheezing or ascertained diagnosis of asthma~* Hypersensitivity to one of the constituting of oral betamethasone~* Vaccination by living vaccine during the preceding 2 weeks

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Months
- Healthy Volunteers: f

Study Arms:
- 0.9% saline solution - oral betamethasone placebo (Type: PLACEBO_COMPARATOR): Control arm: 0.9% saline solution - oral betamethasone placebo
- adrenaline - oral betamethasone (Type: EXPERIMENTAL): Experimental arm : adrenaline and betamethasone

Based on this trial design, predict the completion outcome and termination type (if applicable).